吉利德科学:预计2026财年细胞疗法收入将同比下降10%,反映持续竞争压力

美股速递
Feb 11

吉利德科学在其最新报告中预测,公司2026财年的细胞疗法业务收入预计将出现10%的同比下滑。这一展望凸显了该业务板块当前面临的持续性竞争挑战。随着市场竞争加剧,公司细胞疗法产品的增长势头受到明显制约。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10